Last reviewed · How we verify
Nebivolol Tablets
Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while also promoting nitric oxide-mediated vasodilation.
Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while also promoting nitric oxide-mediated vasodilation. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.
At a glance
| Generic name | Nebivolol Tablets |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Beta-1 selective adrenergic receptor antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nebivolol blocks beta-1 adrenergic receptors on the heart, decreasing heart rate and contractility to lower blood pressure and reduce cardiac workload. Unlike non-selective beta-blockers, it has additional vasodilatory properties mediated through nitric oxide release in endothelial cells, providing additional cardiovascular benefits beyond traditional beta-blockade.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Angina pectoris
- Post-myocardial infarction
Common side effects
- Fatigue
- Dizziness
- Headache
- Bradycardia
- Hypotension
- Dyspnea
Key clinical trials
- Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients (PHASE2)
- Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients (PHASE4)
- Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy (PHASE4)
- Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. (PHASE2, PHASE3)
- Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy (PHASE4)
- Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy (PHASE4)
- Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets (PHASE1)
- Beta-blockade in Unruptured Intracranial Aneurysm (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol Tablets CI brief — competitive landscape report
- Nebivolol Tablets updates RSS · CI watch RSS
- Ain Shams University portfolio CI